Literature DB >> 20838943

Gene therapy for erectile dysfunction: what is the future?

Arnold Melman1, Kelvin Davies.   

Abstract

Gene transfer for the treatment of erectile dysfunction has completed phase 1 safety testing and has shown the necessary safety to proceed to the next level of clinical trial. This review focuses on the background of the components of that have led to US Food and Drug Administration acceptance of human gene transfer trials for nonlethal disease.

Entities:  

Mesh:

Year:  2010        PMID: 20838943     DOI: 10.1007/s11934-010-0145-1

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  14 in total

1.  Virus treatment questioned after gene therapy death.

Authors:  S Lehrman
Journal:  Nature       Date:  1999-10-07       Impact factor: 49.962

Review 2.  Detection and implications of potassium channel alterations.

Authors:  Victoria P Korovkina; Sarah K England
Journal:  Vascul Pharmacol       Date:  2002-01       Impact factor: 5.773

3.  Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder.

Authors:  K S Thorneloe; A L Meredith; A M Knorn; R W Aldrich; M T Nelson
Journal:  Am J Physiol Renal Physiol       Date:  2005-04-12

4.  hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial.

Authors:  Arnold Melman; Natan Bar-Chama; Andrew McCullough; Kelvin Davies; George Christ
Journal:  Hum Gene Ther       Date:  2006-12       Impact factor: 5.695

Review 5.  Potassium channels: molecular defects, diseases, and therapeutic opportunities.

Authors:  C C Shieh; M Coghlan; J P Sullivan; M Gopalakrishnan
Journal:  Pharmacol Rev       Date:  2000-12       Impact factor: 25.468

6.  Erectile dysfunction in mice lacking the large-conductance calcium-activated potassium (BK) channel.

Authors:  Matthias E Werner; Peter Zvara; Andrea L Meredith; Richard W Aldrich; Mark T Nelson
Journal:  J Physiol       Date:  2005-07-14       Impact factor: 5.182

7.  DNA as therapeutics; an update.

Authors:  P Saraswat; R R Soni; A Bhandari; B P Nagori
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

Review 8.  Standards for clinical trials in male sexual dysfunctions.

Authors:  Hartmut Porst; Yoram Vardi; Emre Akkus; Arnold Melman; Nam Cheol Park; Allen D Seftel; Claudio Teloken; Michael Wyllie
Journal:  J Sex Med       Date:  2010-01       Impact factor: 3.802

Review 9.  Gene transfer for erectile dysfunction: will this novel therapy be accepted by urologists?

Authors:  Arnold Melman; Lorraine Rojas; George Christ
Journal:  Curr Opin Urol       Date:  2009-11       Impact factor: 2.309

Review 10.  Gene therapy in the management of erectile dysfunction (ED): past, present, and future.

Authors:  Arnold Melman; Kelvin P Davies
Journal:  ScientificWorldJournal       Date:  2009-08-31
View more
  3 in total

Review 1.  Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms.

Authors:  Kenneth Blum; Tonia Werner; Stefanie Carnes; Patrick Carnes; Abdalla Bowirrat; John Giordano; Marlene Oscar-Berman; Mark Gold
Journal:  J Psychoactive Drugs       Date:  2012 Jan-Mar

Review 2.  Challenges in sexual medicine.

Authors:  Selim Cellek; Annamaria Giraldi
Journal:  Nat Rev Urol       Date:  2012-07-10       Impact factor: 14.432

Review 3.  Gene Therapy for Overactive Bladder: A Review of BK-Channel α-Subunit Gene Transfer.

Authors:  Karl-Erik Andersson; George Joseph Christ; Kelvin P Davies; Eric S Rovner; Arnold Melman
Journal:  Ther Clin Risk Manag       Date:  2021-06-04       Impact factor: 2.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.